
Backed by Alcon’s robust support capabilities, the ALLEGRETTO WAVE® Eye-Q Laser delivers excellent efficiency, accuracy and patient outcomes to enhance your practice performance.

Learn more about how the ALLEGRETTO WAVE® Eye-Q Laser can benefit your practice. www.alconrefractive.com

FDA Approved Clinical Results

Proven Powerful Hyperopic Outcomes

FDA clinical trial results for Wavefront Optimized® correction clearly demonstrate why the ALLEGRETTO WAVE® Eye-Q Laser continues to maintain its category leadership.

After Wavefront Optimized® LASIK, patients reported an improvement in glare from bright lights, light sensitivity, and night driving glare. The percent of subjects reporting “none” or “mild” of these symptoms improved after treatment.¹

Wavefront Optimized® procedures use the power of PerfectPulse Technology® to ensure excellent hyperopia treatment outcomes. This personalized approach enables precise and accurate ablations tailored to each patient’s refractive error.

FDA Approved Clinical Results

Uncorrected Visual Acuity (UCVA) Effectiveness – Hyperopia

More than 67% of patients saw 20/20 or better without glasses after treatment. 95% of patients saw 20/40 or better without glasses after treatment.¹

Best Spectacle Corrected Visual Acuity (BSCVA) – Hyperopia

Nearly 90% of patients remained unchanged or gained one or more lines of BSCVA vision.¹

Change in Post-UCVA vs. Pre-BSCVA – Hyperopia

55% of patients saw at least as good or better without visual aids after the treatment than before with their glasses or contact lenses.¹
More than 97% of both patient groups remained unchanged or gained one or more lines of BSCVA vision.

Uncorrected Visual Acuity (UCVA) Effectiveness - Myopia

Both groups demonstrated similar performance for visual acuity. In both groups, 93% of patients achieved UCVA 20/20 or better after treatment.

A Broad Spectrum of Myopic Vision Correction

The WaveLight® ALLEGRO Wave® Eye-Q Laser in conjunction with the ALLEGRO Analyzer® aberrometer provides effective, customized treatments for patients with higher order aberrations and complex vision correction needs.

All eyes naturally have higher order spherical aberrations. In eyes with relatively normal levels of higher order spherical aberrations, a Wavefront Optimized® treatment has been shown to be effective in producing excellent visual outcomes.

Best Spectacle Corrected Visual Acuity (BSCVA) - Myopia

More than 97% of both patient groups remained unchanged or gained one or more lines of BSCVA vision. Over 50% of all patients gained at least one line over BSCVA.

Change in post-UCVA vs. pre-BSCVA - Myopia

85% of patients saw at least as good or better without visual aids after the treatment (Wavefront Optimized® or Wavefront-Guided) than before with their glasses or contact lenses.